New in Diabetes Technology

Health Professional

The technology revolution in diabetes gadgetry continues to blossom. We will address some latest devices and add a cautionary note about the report of a glitch in one of the insulin pumps (source -Diabetes in

  • mySentry Remote Glucose monitor (FDA approved) works in tandem with the Medtronic Minimed Paradigm Real-Time Revel system that includes the insulin pump with the associated Continuous glucose sensor. The device is a bedside monitor (a la "baby monitors", that will alarm caregivers of changes in blood glucose levels. This is most appropriate and useful for overnight surveillance of blood glucose trends (highs or lows) as well as insulin pump data such as battery charge and the amount of insulin remaining in the pump. Apparently, it can act to prevent a further drop in blood sugar if needed. The device is expensive, costing @$3000.   Please review this informative video if you are interested in this monitor:
  1. Johnson and Johnson's LifeScan division has developed the OneTouch(R) Verio(TM)IQ System with PatternAlert TM. _ _According to LifeScan, the technology of this new blood glucose meter is enabled to search for high and low blood glucose patterns, and provides on-screen alerts. Messages will alert to patterns in which your blood sugar is low at particular times of day. The goal of the new meter is to help point out patterns without necessarily downloading the meter's data onto a computer software program and to provide the information during real-time. OneTouch®** Verio**TM IQ | (A disclosure is in order: I am a LifeScan consultant associated with the development of this meter)
  2. Insulin pumps:
  1. Animas One Touch Ping:   The FDA has issued a warning to Johnson and Johnson that sanctions may be issued for selling faulty One Touch Pings and Animas 2020 pump and apparently delaying the release of information about injuries that were using these devices. The FDA ordered Animas Corp to explain the reasoning for distributing pumps that were known to fail and submit a plan to promptly fix the failures. What were the problems? Apparently some pump keypads that control the amount of insulin injected were "deteriorating prematurely", thus leading to failures and prompting Animas Corp to develop a more durable keypad. The issue was that Animas Corp continued to sell the pumps with old keypads despite having the above information. According to Diabetes in, "The FDA's warning letter states that the initial Animas response to the problems cited in the August inspection report was not adequate. Animas hopes to respond before the January 20, 2012 deadline".
  2. Tandem t:** slim:** Tandem Diabetes Care, Inc. 's new pump received FDA approval on 11.16.11 to begin marketing. The pump is described as "revolutionary" as the system is powered by "pressure with a micro dosing mechanism able to deliver tiny does in 0.001 unit increments." The t:slim has no motor and fewer parts than the currently available insulin pumps. According to the company, it will not over-deliver insulin during the pressure drops that occur during air travel (the pressure drops in an airplane after takeoff). The pump has a touch screen interface, rechargeable battery, pump settings on one page (very helpful for those that have to make changes), rapid USB download to "t:connect" (tandem's online application) for reports as well as no airplane or gravity issues as described above.   The cartridge holds up to 300 units. Finally, the pump is expected to be released in the second quarter of 2012.

Once again, I would like all to keep in mind that these devices are merely adjuncts to diabetes management and may improve quality of life! Human decision- making and self-care skills still remain the most important tools in managing diabetes!